Ropes & Gray LLP is a global law firm providing corporate, finance, litigation, regulatory, and intellectual property counsel to public and private companies, financial sponsors, and institutions across the U.S., Europe, and Asia.
For clients in the chemicals, life sciences, and advanced materials sectors, the firm advises on mergers and acquisitions, private equity investments, capital markets transactions, joint ventures, licensing and collaborations, antitrust, and disputes. Its work also covers compliance and investigations, data and cybersecurity, trade controls and sanctions, and regulatory matters including product safety and environmental considerations. The firm’s cross-disciplinary teams support complex transactions, IP strategy and enforcement, supply and manufacturing arrangements, and cross‑border issues relevant to companies operating across the chemicals value chain.
Precision platform targets pathogenic autoantibodies; MER511 Phase 1 shows strong reductions in thyroid‑stimulating antibodies; deal includes up to $2.875B in cash.
Adds BPL-003 (mebufotenin benzoate intranasal) and VLS-01 (DMT buccal); upfront $6.75/share plus up to $2.50/share CVR tied to development, regulatory and DEA-rescheduling milestones.
Includes two late-stage ROS1 and ALK NSCLC inhibitors under FDA review for 2026 decisions, plus a HER2 candidate; expected to be accretive to profit from 2027 and funded by debt and cash.
Lead program in Phase 1; POC data due late 2026. Designed to deliver deeper, more durable responses than current Type I JAK2 therapies. Deal may pay up to $2.3B, subject to closing.
Ventyx's small molecule pipeline targets chronic inflammation in cardiometabolic, neurodegenerative, and inflammatory diseases, aiming for improved efficacy and safety.
Lilly's tender offer for Adverum shares expired, with 64% tendered. Acquisition completion expected Dec. 9, 2025. Legal and financial advisors involved.
Novo Nordisk acquires Akero for $4.7B, adding efruxifermin, a promising MASH treatment, to its portfolio. The deal includes a $0.5B contingent value right upon regulatory approval.
